With a potential savings of over $100 million over the next five years, spend on biologics continues to outpace the total market by a two-to-one margin. However, utilization rates in the United States have been slowed by numerous issues.

Wendy Biese and Carmen Gust join this episode to discuss the strategies ThedaCare Regional Medical Center has adopted to optimize biosimilars, and some of the barriers they’ve had to overcome in order to achieve their successful results.

Speakers:

Wendy Biese, PharmD, DPLA

System Director – Pharmacy Services

ThedaCare Regional Medical Center

Carmen Gust, PharmD, BCPS

System Clinical Pharmacy Coordinator

ThedaCare Regional Medical Center

Moderator

Jim Lichauer, PharmD, BCPS, FASHP

Sr PI Program Director, Pharmacy

Vizient

Show Notes:

[00.05] Background information on biosimilars and the history of biologics spend.

[01:40] Background information about ThedaCare.

[03:42] ThedaCare’s initial work with biosimilar conversion, from 2018 to early 2022.

[05:57] How ThedaCare’s game-changer initiative began, in the cancer center, and how key stakeholders were engaged.

[09:37] ThedaCare’s best practices for actively converting patients to biosimilars.

[12:04] Results so far, including outcomes and projected savings.

[13:01] Advice for organizations planning to implement similar biosimilar strategies.

[15:21] How ThedaCare is moving into the next phase of biosimilar conversion, and strategies for overcoming challenges.

Subscribe Today!

Apple Podcasts

Amazon Podcasts

Spotify

Google Podcasts

Android

Stitcher

RSS Feed